# Real-world evaluation of ceftriaxone-related safety events: a stewardship call to action

**Authors:** Kristen Paciullo, Sujit Suchindran, Leila S. Hojat, Benjamin Albrecht, Sarah B. Green, K. Ashley Jones, Daniel J. Rogers, Trinh P. Vu, Lucy S. Witt

PMC · DOI: 10.1017/ash.2025.10258 · 2025-12-22

## TL;DR

This study evaluated ceftriaxone safety in real-world use and found few serious adverse events, similar to other cephalosporins.

## Contribution

The study provides real-world evidence on ceftriaxone safety, addressing a recent safety alert with large-scale data.

## Key findings

- Ceftriaxone-related adverse events were rare despite high usage.
- Event rates were similar to other intravenous cephalosporins.
- Findings support continued cautious use of ceftriaxone.

## Abstract

A ceftriaxone safety alert prompted a review of rapid response and cardiac arrest events in relation to the timing of intravenous cephalosporin administrations across a large health system. Despite high utilization, we found a low rate of significant ceftriaxone-related adverse events with a similar incidence as other intravenous cephalosporins.

## Linked entities

- **Chemicals:** ceftriaxone (PubChem CID 5479530), cephalosporins (PubChem CID 25058126)

## Full-text entities

- **Diseases:** cardiac arrest (MESH:D006323)
- **Chemicals:** cephalosporin (MESH:D002511), ceftriaxone (MESH:D002443)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12766508/full.md

---
Source: https://tomesphere.com/paper/PMC12766508